title: Comparison of front-line chemotherapy for aggressive non-Hodgkin's lymphoma using the CAP-BOP regimens. The Nebraska Lymphoma Study Group.
authors.affiliation: Department of Internal Medicine, University of Nebraska, Omaha 68198-3330.
authors.forename: J M
authors.initials: JM
authors.lastname: Vose
authors.forename: J R
authors.initials: JR
authors.lastname: Anderson
authors.forename: P J
authors.initials: PJ
authors.lastname: Bierman
authors.forename: M
authors.initials: M
authors.lastname: Bast
authors.forename: D
authors.initials: D
authors.lastname: Weisenburger
authors.forename: W C
authors.initials: WC
authors.lastname: Chan
authors.forename: M R
authors.initials: MR
authors.lastname: Bishop
authors.forename: J O
authors.initials: JO
authors.lastname: Armitage
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D011344:Procarbazine / Q000008:administration & dosage / Q000009:adverse effects; D011379:Prognosis; D015996:Survival Rate; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D001761:Bleomycin; D011344:Procarbazine; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone